Targeted drug delivery system for oral cancer therapy using sonoporation
Targeted drug delivery system for oral cancer therapy using sonoporation
复制标题
DOI：
10.1111/j.1600-0714.2009.00759.x
复制
发表时间：
2009-08-01
影响因子：
3.3
通讯作者：
Nishihara, Tatsuji
中科院分区：
文献类型：
--
作者：
Maeda, Hironobu;Tominaga, Kazuhiro;Nishihara, Tatsuji
超声介导的微泡破坏已被提出作为一种创新的非侵入性药物递送系统用于癌症治疗。我们开发了一种针对鳞状细胞癌的特异性药物递送系统，该系统使用抗表皮生长因子受体（EGFR）抗体的声孔效应。低剂量博莱霉素（BLM）与抗EGFR抗体通过声孔作用的管理产生了显着的生长抑制Ca 9 -22细胞在体外。此外，扫描电子显微镜分析显示，在抗体的存在下，用声致穿孔处理的Ca 9 -22细胞的明显表面变形。有趣的是，当使用声致孔法用抗EGFR抗体的Fab片段递送低剂量的BLM时，凋亡细胞的群体显著增加。这些研究结果表明，声致孔与Fab片段，使它有可能给药到细胞更有效地和具体的，这表明一个新的应用化疗和基因治疗治疗口腔鳞状细胞癌。
Ultrasound-mediated destruction of microbubbles has been proposed as an innovative non-invasive drug delivery system for cancer therapy. We developed a specific drug delivery system for squamous cell carcinoma that uses sonoporation with the anti-epidermal growth factor receptor (EGFR) antibody. Administration of a low dose of bleomycin (BLM) by sonoporation with the anti-EGFR antibody produced a marked growth inhibition of Ca9-22 cells in vitro. In addition, scanning electron microscopic analysis revealed apparent surface deformation of Ca9-22 cells treated with sonoporation in the presence of the antibody. Interestingly, the population of apoptotic cells was remarkably increased when a low dose of BLM was delivered using sonoporation with the Fab fragment of the anti-EGFR antibody. These findings indicate that sonoporation with the Fab fragment makes it possible to administer drugs into cells more efficiently and specifically, suggesting a novel application for chemotherapy and gene therapy treatments for oral squamous cell carcinoma.